Treatment of Refractory Crohn's Disease and Pyoderma Gangrenosum with a Combination Regimen of Rifaximin, Gentamicin and Metronidazole

The etiology of Crohn's disease (CD) remains controversial. It is hypothesized that CD is the result of an abnormal immune response to the gut flora in genetically susceptible hosts. However, an infectious etiology has not been completely ruled out. Antibiotics have been utilized with some succ...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldberg, Neil D., Vadlamudi, Aravinda, Parrish, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2015
Materias:
Published online: January, 2015
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342856/
https://www.ncbi.nlm.nih.gov/pubmed/25802494
http://dx.doi.org/10.1159/000369965
_version_ 1782359329268039680
author Goldberg, Neil D.
Vadlamudi, Aravinda
Parrish, Nicole
author_facet Goldberg, Neil D.
Vadlamudi, Aravinda
Parrish, Nicole
author_sort Goldberg, Neil D.
collection PubMed
description The etiology of Crohn's disease (CD) remains controversial. It is hypothesized that CD is the result of an abnormal immune response to the gut flora in genetically susceptible hosts. However, an infectious etiology has not been completely ruled out. Antibiotics have been utilized with some success to modify the course of the disease. Here, we report a patient with CD and pyoderma gangrenosum refractory to standard therapy, including biologics, who achieved remission with a combination of rifaximin, gentamicin and metronidazole.
format Online
Article
Text
id pubmed-4342856
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-43428562015-03-23 Treatment of Refractory Crohn's Disease and Pyoderma Gangrenosum with a Combination Regimen of Rifaximin, Gentamicin and Metronidazole Goldberg, Neil D. Vadlamudi, Aravinda Parrish, Nicole Case Rep Gastroenterol Published online: January, 2015 The etiology of Crohn's disease (CD) remains controversial. It is hypothesized that CD is the result of an abnormal immune response to the gut flora in genetically susceptible hosts. However, an infectious etiology has not been completely ruled out. Antibiotics have been utilized with some success to modify the course of the disease. Here, we report a patient with CD and pyoderma gangrenosum refractory to standard therapy, including biologics, who achieved remission with a combination of rifaximin, gentamicin and metronidazole. S. Karger AG 2015-01-24 /pmc/articles/PMC4342856/ /pubmed/25802494 http://dx.doi.org/10.1159/000369965 Text en Copyright © 2015 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: January, 2015
Goldberg, Neil D.
Vadlamudi, Aravinda
Parrish, Nicole
Treatment of Refractory Crohn's Disease and Pyoderma Gangrenosum with a Combination Regimen of Rifaximin, Gentamicin and Metronidazole
title Treatment of Refractory Crohn's Disease and Pyoderma Gangrenosum with a Combination Regimen of Rifaximin, Gentamicin and Metronidazole
title_full Treatment of Refractory Crohn's Disease and Pyoderma Gangrenosum with a Combination Regimen of Rifaximin, Gentamicin and Metronidazole
title_fullStr Treatment of Refractory Crohn's Disease and Pyoderma Gangrenosum with a Combination Regimen of Rifaximin, Gentamicin and Metronidazole
title_full_unstemmed Treatment of Refractory Crohn's Disease and Pyoderma Gangrenosum with a Combination Regimen of Rifaximin, Gentamicin and Metronidazole
title_short Treatment of Refractory Crohn's Disease and Pyoderma Gangrenosum with a Combination Regimen of Rifaximin, Gentamicin and Metronidazole
title_sort treatment of refractory crohn's disease and pyoderma gangrenosum with a combination regimen of rifaximin, gentamicin and metronidazole
topic Published online: January, 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342856/
https://www.ncbi.nlm.nih.gov/pubmed/25802494
http://dx.doi.org/10.1159/000369965
work_keys_str_mv AT goldbergneild treatmentofrefractorycrohnsdiseaseandpyodermagangrenosumwithacombinationregimenofrifaximingentamicinandmetronidazole
AT vadlamudiaravinda treatmentofrefractorycrohnsdiseaseandpyodermagangrenosumwithacombinationregimenofrifaximingentamicinandmetronidazole
AT parrishnicole treatmentofrefractorycrohnsdiseaseandpyodermagangrenosumwithacombinationregimenofrifaximingentamicinandmetronidazole

Ejemplares similares